STAT+: Pharmalittle: Pfizer to boost Covid-19 vaccine production for the U.S.; J&J faces new test with Covid-shot pause
Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of online meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day, and, as always, do drop us a line when you hear something interesting. …
Pfizer (PFE) has ramped up production of its Covid-19 vaccine and expects to have delivered a total of 300 million doses to the U.S. two weeks early, in July, CNBC tells us. The drug maker expects to deliver 10% more doses to the U.S. by the end of May than it had previously agreed to — up to 220 million from 200 million. The announcement came as dozens of states temporarily stopped administering the Johnson & Johnson (JNJ) single-dose Covid vaccine following a Food and Drug Administration advisory.
Continue to STAT+ to read the full story…
